Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia

https://www.businesswire.com/news/home/20200917006062/en/Genentech%E2%80%99s-Phase-III-EMPACTA-Study-Showed-Actemra-Reduced-the-Likelihood-of-Needing-Mechanical-Ventilation-in-Hospitalized-Patients-With-COVID-19-Associated-Pneumonia?utm_source=STAT+Newsletters&utm_campaign=5aa95a0553-EMAIL_CAMPAIGN_2020_09_20_10_47&utm_medium=email&utm_term=0_8cab1d7961-5aa95a0553-149692869

Genentech Covid-19 trial both diverse and effective

A Genentech rheumatoid arthritis drug helped temper the severity of pneumonia in people with Covid-19, new Phase 3 data show. Patients who received Actemra, or tocilizumab, in addition to standard care, were 44% less likely to be placed on a ventilator or die, the company said. About 12% of volunteers in the Actemra arm needed a mechanical ventilator or died, compared to about 19% in the placebo arm. 

One noteworthy aspect of this trial: About 85% of the 389 participants in the trial were Hispanic, Black, or Native American. These minorities have historically been underrepresented in trials, but are disproportionately affected by the Covid-19 pandemic.